The Food and Drug Administration asked Arrowhead Research Corp. (Nasdaq: ARWR)
to lower the dosage of its hepatitis B treatment ARC-520 in a Phase 2b
study. The stock price plunged $2.16 to close at $6.90.
Arrowhead Research must modify study
January 12, 2015 at 15:59 PM EST
